Swedish Dental Association

Recent papers from Swedish Dental Association

1. Regulatory Research Priorities for AI Use in the Medicine Lifecycle: A European Perspective with Global RelevanceClinical Pharmacology & Therapeutics · 2026
2. Transferability of Real World Evidence to Support HTA Recommendations in Lower Income European CountriesHealth Science Reports · 2026
3. Actions for stakeholders to develop better real-world evidence for HTA bodies/payers decision makingInternational Journal of Technology Assessment in Health Care · 2025
4. Linking Reimbursement to Patient Benefits for Advanced Therapy Medicinal Products and Other High-Cost Innovations: Policy Recommendations for Outcomes-Based Agreements in EuropeValue in Health · 2024
5. Consolidated Health Economic Evaluation Reporting Standards for Interventions That Use Artificial Intelligence (CHEERS-AI)Value in Health · 2024
6. The relationship between practice ownership and follow-up of comprehensive dental care. A Swedish register studyActa Odontologica Scandinavica · 2024
7. Validation of overall survival extrapolations made by TLV in the assessment of cost-effectiveness of oncology drugs in Sweden – A pilot study comparing extrapolated and observed life-years gainedJournal of Medical Economics · 2024
8. Barriers to Use Artificial Intelligence Methodologies in Health Technology Assessment in Central and East European CountriesSHILAP Revista de lepidopterología · 2022
9. Using real-world evidence in healthcare from Western to Central and Eastern Europe: a review of existing barriersJournal of Comparative Effectiveness Research · 2022
10. Real World Data in Health Technology Assessment of Complex Health TechnologiesFrontiers in Pharmacology · 2022
11. Variation in the prices of oncology medicines across Europe and the implications for the futureGenerics and Biosimilars Initiative Journal · 2021
12. MYCN-enhanced Oxidative and Glycolytic Metabolism Reveals Vulnerabilities for Targeting NeuroblastomaiScience · 2019
13. Unmet Medical Need: An Introduction to Definitions and Stakeholder PerceptionsValue in Health · 2019
14. Pricing of oral generic cancer medicines in 25 European countries; findings and implicationsGenerics and Biosimilars Initiative Journal · 2019
15. Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s DiseaseCNS Drugs · 2018
16. The impact of parallel regulatory–health technology assessment scientific advice on clinical development. Assessing the uptake of regulatory and health technology assessment recommendationsBritish Journal of Clinical Pharmacology · 2018
17. How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory‐HTA parallel scientific adviceBritish Journal of Clinical Pharmacology · 2016
18. Access to Healthcare among People with Physical Disabilities in Rural LouisianaSocial Work in Public Health · 2016
19. Generic pregabalin; current situation and implications for health authorities, generics and biosimilars manufacturers in the futureGenerics and Biosimilars Initiative Journal · 2015
20. Swedish experience-based value sets for EQ-5D health statesQuality of Life Research · 2013